OBJECTIVE: To describe results of cervical cytology screening among low-income and uninsured women in the National Breast and Cervical Cancer Early Detection Program. METHODS: We analyzed data from 750,591 women who received their first Papanicolaou (Pap) test in the program between July 1995 and March 2001. RESULTS: Nearly 85% of the women were aged 40 years or older. Almost half were members of racial or ethnic minority groups. Overall, the percentage of abnormal Pap test results decreased with increasing age. The rates of cervical intraepithelial neoplasia (CIN) were highest in the younger age groups but the rate of invasive cancer increased with age. White women had the highest age-adjusted percentage of abnormal Pap test results and the highest rate of biopsy-confirmed CIN 2 or worse. CONCLUSIONS: In this nationwide screening program, only 7% of all biopsy-confirmed high-grade cervical lesions (CIN 2 or worse) were invasive cancer. This underscores the success of Pap screening in identifying preinvasive disease and preventing cancer. LEVEL OF EVIDENCE: II-3
OBJECTIVE: To describe results of cervical cytology screening among low-income and uninsured women in the National Breast and Cervical Cancer Early Detection Program. METHODS: We analyzed data from 750,591 women who received their first Papanicolaou (Pap) test in the program between July 1995 and March 2001. RESULTS: Nearly 85% of the women were aged 40 years or older. Almost half were members of racial or ethnic minority groups. Overall, the percentage of abnormal Pap test results decreased with increasing age. The rates of cervical intraepithelial neoplasia (CIN) were highest in the younger age groups but the rate of invasive cancer increased with age. White women had the highest age-adjusted percentage of abnormal Pap test results and the highest rate of biopsy-confirmed CIN 2 or worse. CONCLUSIONS: In this nationwide screening program, only 7% of all biopsy-confirmed high-grade cervical lesions (CIN 2 or worse) were invasive cancer. This underscores the success of Pap screening in identifying preinvasive disease and preventing cancer. LEVEL OF EVIDENCE: II-3
Authors: Douglas C A Taylor; Vivek Pawar; Denise T Kruzikas; Kristen E Gilmore; Myrlene Sanon; Milton C Weinstein Journal: Pharmacoeconomics Date: 2012-02-01 Impact factor: 4.981
Authors: Douglas C A Taylor; Vivek Pawar; Denise Kruzikas; Kristen E Gilmore; Ankur Pandya; Rowan Iskandar; Milton C Weinstein Journal: Pharmacoeconomics Date: 2010 Impact factor: 4.981
Authors: Vicki B Benard; Meg Watson; Mona Saraiya; Rhea Harewood; Julie S Townsend; Antoinette M Stroup; Hannah K Weir; Claudia Allemani Journal: Cancer Date: 2017-12-15 Impact factor: 6.860
Authors: Virginia Senkomago; Janet Royalty; Jacqueline W Miller; Lee E Buenconsejo-Lum; Vicki B Benard; Mona Saraiya Journal: Cancer Epidemiol Date: 2017-10 Impact factor: 2.984
Authors: Karla K Evans; Rosemary H Tambouret; Andrew Evered; David C Wilbur; Jeremy M Wolfe Journal: Arch Pathol Lab Med Date: 2011-12 Impact factor: 5.534
Authors: Denise J Jamieson; Metrecia L Terrell; Nnenna N Aguocha; Chanley M Small; Lorraine L Cameron; Michele Marcus Journal: J Womens Health (Larchmt) Date: 2011-07-28 Impact factor: 2.681
Authors: Christie R Eheman; Steven Leadbetter; Vicki B Benard; A Blythe Ryerson; Janet E Royalty; Donald Blackman; Lori A Pollack; Paula Willey Adams; Fran Babcock Journal: Cancer Date: 2014-08-15 Impact factor: 6.860
Authors: Sandi L Pruitt; Matthew J Shim; Patricia Dolan Mullen; Sally W Vernon; Benjamin C Amick Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-10 Impact factor: 4.254